Empagliflozin + Linagliptin
Generic Details
Generic Name
Empagliflozin-Linagliptin
Other Names
- Glyxambi
Drug Class
- Antidiabetic Combination
Chemical Formula
C25H28F2N4O2-C25H28N8O2
Molecular Weight
516.53 g/mol - 728.61 g/mol
Mechanism of Action
- Empagliflozin: SGLT2 Inhibitor
- Linagliptin: DPP-4 Inhibitor
Indications
- Type 2 Diabetes Mellitus
Common Dosage Forms
- Tablet
Typical Dosage
- 10 mg empagliflozin/5 mg linagliptin once daily
Pediatric Dosage
- Not established
Geriatric Dosage
- Adjust dose based on renal function
Side Effects
- Hypoglycemia
- Urinary Tract Infections
- Increased urination
- Hypersensitivity reactions
Contraindications
- Severe renal impairment
- End-stage renal disease
- Hypersensitivity to components
Pregnancy Category
- Category C
Lactation Safety
- Unknown, avoid breastfeeding
Drug Interactions
- Diuretics
- Insulin
- Beta-blockers
Overdose Symptoms
- Dehydration
- Electrolyte imbalances
Antidote for Overdose
- Supportive care
Storage Conditions
- Store at room temperature (20-25°C)
Pharmacokinetics
- Absorption: Well absorbed
- Distribution: Protein-bound
- Metabolism: Metabolized by liver enzymes
- Excretion: Renal and fecal excretion
Precautions
- Monitor renal function regularly
- Monitor for signs of ketoacidosis
Warnings
- Risk of ketoacidosis
- Potential genital mycotic infections
Others
- Empagliflozin-linagliptin combination provides complementary mechanisms to improve blood sugar control.